<SEC-DOCUMENT>0001437749-24-003357.txt : 20240207
<SEC-HEADER>0001437749-24-003357.hdr.sgml : 20240207
<ACCEPTANCE-DATETIME>20240207160621
ACCESSION NUMBER:		0001437749-24-003357
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20240205
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240207
DATE AS OF CHANGE:		20240207

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CervoMed Inc.
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				300645032
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37942
		FILM NUMBER:		24604304

	BUSINESS ADDRESS:	
		STREET 1:		20 PARK PLAZA
		STREET 2:		SUITE 424
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		(617) 744-4400

	MAIL ADDRESS:	
		STREET 1:		20 PARK PLAZA
		STREET 2:		SUITE 424
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Diffusion Pharmaceuticals Inc.
		DATE OF NAME CHANGE:	20160115

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RestorGenex Corp
		DATE OF NAME CHANGE:	20140307

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stratus Media Group, Inc
		DATE OF NAME CHANGE:	20080722
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>crvo20240205_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:crvo="http://www.crvo.com/20240205"><head>
	<title>crvo20240205_8k.htm</title>

	<!-- Generated by ThunderDome Portal - 2/6/2024 11:32:28 PM -->
<meta http-equiv="Content-Type" content="text/html"/></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20248K" name="dei:AmendmentFlag" id="ixv-360">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20248K" name="dei:EntityCentralIndexKey" id="ixv-361">0001053691</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="crvo-20240205.xsd" xlink:type="simple"/>
</ix:references>
<ix:resources>
<xbrli:context id="d20248K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2024-02-05</xbrli:startDate>
<xbrli:endDate>2024-02-05</xbrli:endDate>
</xbrli:period>
</xbrli:context>



</ix:resources>
</ix:header>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&#160;</div>

<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/>
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0"/>
<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b></div>

<div style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#160;</div>

<div style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM <ix:nonNumeric contextRef="d20248K" name="dei:DocumentType" id="ixv-22"><b>8-K</b></ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CURRENT REPORT</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Pursuant to Section 13 or 15(d)</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>of The Securities Exchange Act of 1934</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20248K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="ixv-35"><b>February 5, 2024</b></ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date of Report (Date of earliest event reported)</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#160;</div>

<div style="font-family:Times New Roman;font-size:24pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityRegistrantName" id="ixv-43"><b>CervoMed Inc.</b></ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Exact name of registrant as specified in its charter)</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 30%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-55"><b>Delaware</b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
			<td style="vertical-align: top; width: 30%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityFileNumber" id="ixv-60"><b>001-37942</b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
			<td style="vertical-align: top; width: 30%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityTaxIdentificationNumber" id="ixv-65"><b>30-0645032</b></ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 30%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(State or other jurisdiction</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>of incorporation)</b></div>
			</td>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
			<td style="vertical-align: top; width: 30%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Commission</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>File Number)</b></div>
			</td>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
			<td style="vertical-align: top; width: 30%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(I.R.S. Employer</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Identification No.)</b></div>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align: middle; width: 35%;">&#160;</td>
			<td colspan="2" style="vertical-align: middle; width: 5%;">&#160;</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align: top; width: 35%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityAddressAddressLine1" id="ixv-91"><b>20 Park Plaza, Suite 424</b></ix:nonNumeric></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20248K" name="dei:EntityAddressCityOrTown" id="ixv-95"><b>Boston</b></ix:nonNumeric>, <ix:nonNumeric contextRef="d20248K" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="ixv-97"><b>Massachusetts</b></ix:nonNumeric></b></div>
			</td>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
			<td style="vertical-align: bottom; width: 30%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityAddressPostalZipCode" id="ixv-102"><b>02116</b></ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align: top; width: 35%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Address of principal executive offices)</b></div>
			</td>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
			<td style="vertical-align: top; width: 30%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Zip Code)</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Registrant</b>&#8217;<b>s telephone number, including area code: (<ix:nonNumeric contextRef="d20248K" name="dei:CityAreaCode" id="ixv-116"><b>617</b></ix:nonNumeric>) <ix:nonNumeric contextRef="d20248K" name="dei:LocalPhoneNumber" id="ixv-118"><b>744-4400</b></ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Not applicable</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Former name or former address, if changed since last report)</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="ixv-371">&#9744;</ix:nonNumeric>&#160; &#160; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="ixv-372">&#9744;</ix:nonNumeric>&#160; &#160; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="ixv-373">&#9744;</ix:nonNumeric>&#160; &#160; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="ixv-374">&#9744;</ix:nonNumeric>&#160; &#160; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Title of each class</b></div>
			</td>
			<td style="vertical-align:bottom;width:auto;">&#160;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Trading</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Symbol(s)</b></div>
			</td>
			<td style="vertical-align:bottom;width:auto;">&#160;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name of each exchange</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>on which registered</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20248K" name="dei:Security12bTitle" id="ixv-375">Common Stock</ix:nonNumeric>, $0.001 par value</div>
			</td>
			<td style="vertical-align:bottom;width:auto;">&#160;</td>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20248K" name="dei:TradingSymbol" id="ixv-376">CRVO</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:bottom;width:auto;">&#160;</td>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-377">NASDAQ</ix:nonNumeric> Capital Market</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Emerging growth company&#160; &#160;&#160;<ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-378">&#9744;</ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160; &#160;&#160;&#9744;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/>
<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0"/>
<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 54pt;text-indent:-54pt;"><b>Item 5.02</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Appointment of Joshua S. Boger, Ph.D., as Director and Chair of the Board</i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On February 5, 2024, the Board of Directors (the &#8220;Board&#8221;) of CervoMed Inc. (the &#8220;Company&#8221;) appointed Joshua S. Boger, Ph.D., as a director of the Company and as Chair of the Board, effective February 7, 2024.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dr. Boger, age 72, is the founder of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) (&#8220;Vertex&#8221;) and served as Vertex&#8217;s Chief Executive Officer from 1992 to May 2009, as chairman of its board of directors from 1997 to 2006 and president from its inception until December 2000 and from 2005 through February 2009, and as a director from 1989 until his retirement from the Vertex board of directors in 2017. Prior to founding Vertex in 1989, Dr. Boger held the position of Senior Director of Basic Chemistry at Merck Sharp &amp; Dohme Research Laboratories in Rahway, New Jersey, where he headed both the Department of Medicinal Chemistry of Immunology &amp; Inflammation and the Department of Biophysical Chemistry. Dr. Boger currently serves as executive chairman of the board of directors of Alkeus Pharmaceuticals, Inc., a privately-held biotechnology company focused on treating degenerative eye diseases. Dr. Boger holds a B.A. in chemistry and philosophy from Wesleyan University and M.S. and Ph.D. degrees in chemistry from Harvard University.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In connection with his appointment to the Board, we expect to grant Dr. Boger a stock option to purchase 10,000 shares of the Company&#8217;s common stock. The option grant will have an exercise price equal to the closing price of the Company&#8217;s common stock on February 12, 2024, the anticipated grant date of the award, will vest in 36 equal monthly installments on the last calendar day of each month commencing February 29, 2024 and will be subject to the other terms and conditions set forth in the Company&#8217;s 2015 Equity Incentive Plan, as amended, and its standard form of option award agreement. In addition to the option grant, (i) Dr. Boger will receive the other cash and equity compensation payable to the Company&#8217;s non-employee directors pursuant to its non-employee director compensation policy (pro-rated as applicable to reflect the actual time Dr. Boger will serve on the Board for the year). and (ii) effective upon his election to the Board, the Company and Dr. Boger entered into the Company&#8217;s standard form of director and officer indemnification agreement.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Effective upon Dr. Boger&#8217;s election as a director of the Company, the size of the Board was expanded from seven to eight members and Dr. Boger will serve for a term to continue until the Company&#8217;s next annual meeting of stockholders. Dr. Boger will not serve on any of the Board&#8217;s standing committees. There are no arrangements or understandings between Dr. Boger and any other persons pursuant to which Dr. Boger was selected as a director of the Company and there are also no family relationships between Dr. Boger and any director or executive officer of the Company.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Certain Relationships and Related Party Transactions</i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In December 2020, EIP Pharma, Inc., the Company&#8217;s wholly-owned subsidiary (&#8220;EIP&#8221;), issued convertible promissory notes (as amended, the &#8220;2020 Notes&#8221;) to certain investors for aggregate proceeds of $5,078,500 and, in December 2021, EIP issued convertible promissory notes (as amended, the &#8220;2021 Notes,&#8221; and together with the 2020 Notes, the &#8220;EIP Convertible Notes&#8221;) to certain investors for aggregate proceeds of $6,000,000. Dr. Boger and certain affiliated trusts purchased $500,000 of the 2020 Notes and $5,000,000 of the 2021 Notes.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In June&#160;2023, EIP and the holders of the EIP Convertible Notes amended the terms and conditions of the EIP Convertible Notes (the &#8220;2023Amendment&#8221;) to, among other things, establish a fixed conversion price of $1.47 with respect to any conversion in connection with the then-pending merger (the &#8220;Merger&#8221;) of EIP and the Company&#8217;s wholly-owned subsidiary, Dawn Merger Sub Inc. (&#8220;Merger Sub&#8221;), pursuant to the Agreement and Plan of Merger, dated March 30, 2023, by and among the Company, EIP and Merger Sub (the &#8220;Merger Agreement&#8221;). In addition, the 2023 Amendment amended the 2021 Notes to provide that, to the extent the conversion of such notes in connection with the Merger were to result in the holder beneficially owning more than 9.99% of the outstanding voting stock of the Company, such holder would be granted pre-funded warrants in lieu of such common stock for the conversion of any principal and accrued but unpaid interest in excess of 9.99%.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In July 2023, EIP sold and issued 472,303 shares of EIP common stock to Dr. Boger for a total purchase price of $694,286.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On August 16, 2023, in connection with the consummation of the Merger, (i) all outstanding shares of EIP preferred stock automatically converted into shares of EIP common stock, (ii) all EIP Convertible Notes (including all principal and all accrued but unpaid interest thereunder) converted into shares of EIP common stock and (iii) after giving effect to the each of the foregoing, each outstanding share of EIP capital stock was converted into the right to receive 0.1151 shares of the Company&#8217;s common stock (or, as applicable, pre-funded warrants to purchase an equivalent number of shares of the Company&#8217;s common stock).</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
2
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of February 7, 2024, Dr. Boger beneficially owns 561,309 shares of the Company&#8217;s common stock, or approximately 9.90% of the Company&#8217;s shares of common stock outstanding as of such date, as well as pre-funded warrants to purchase an additional 495,995 shares of the Company&#8217;s common stock at an exercise price of $0.001 per share, subject to certain limitations with respect to any exercise that would result in Dr. Boger beneficially owning in excess of 9.99% of the Company&#8217;s common stock after giving effect to such exercise. A copy of the form of pre-funded warrant is attached hereto as Exhibit 4.1 and is incorporated herein by reference.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On March 30, 2023, in connection with the execution of the Merger Agreement, the Company and Dr. Boger entered into a lock-up agreement (the &#8220;Lock-Up Agreement&#8221;), pursuant to which the Dr. Boger agreed not to, except in limited circumstances, transfer, grant an option with respect to, sell, exchange, pledge or otherwise dispose of, or encumber any shares of the Common Stock for six months following the effective time of the Merger.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For a further description of the EIP Convertible Notes and the transactions described above, refer to the Company&#8217;s Quarterly Report on Form 10-Q for the period ended September 30, 2023, filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on November 13, 2023 and its other filings with the SEC.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 8.01</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Other Events</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Appointment of Joshua S. Boger, Ph.D., as Director and Chair of the Board</i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On February 7, 2024, the Company issued a press release announcing the election of Dr. Boger as a director and as Chair of the Board. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Participation in Emerging Growth Conference 67</i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On February 5, 2024, the Company issued a press release announcing that members of the Company&#8217;s senior management team will present at the Emerging Growth Conference 67 on Wednesday, February 7, 2024 at 3:50 p.m. ET. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 54pt;text-indent:-54pt;"><b>Item 9.01</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Financial Statements and Exhibits</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>(d)</i></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b><i>Exhibits</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: bottom; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Exhibit No.</b></div>
			</td>
			<td style="vertical-align: bottom; width: 3%;">&#160;</td>
			<td style="vertical-align: bottom; width: 87%; border-bottom: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Description</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">&#160;</td>
			<td style="vertical-align: middle; width: 3%;">&#160;</td>
			<td style="vertical-align: middle; width: 87%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.1</div>
			</td>
			<td style="vertical-align: top; width: 3%;">&#160;</td>
			<td style="vertical-align: top; width: 87%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774923024064/ex_562003.htm" style="-sec-extract:exhibit;">Form of Pre-Funded Warrant (Incorporated by reference to Exhibit 4.3 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on August 17, 2023)</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">99.1</div>
			</td>
			<td style="vertical-align: top; width: 3%;">&#160;</td>
			<td style="vertical-align: top; width: 87%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_623386.htm" style="-sec-extract:exhibit;">Press Release issued February 7, 2024 announcing appointment of Joshua S. Boger as Chair of the Board</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">99.2</div>
			</td>
			<td style="vertical-align: top; width: 3%;">&#160;</td>
			<td style="vertical-align: top; width: 87%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_622961.htm" style="-sec-extract:exhibit;">Press Release issued February 5, 2024 announcing participation in Emerging Growth Conference 67</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">104</div>
			</td>
			<td style="vertical-align: top; width: 3%;">&#160;</td>
			<td style="vertical-align: top; width: 87%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</div>
			</td>
		</tr>

</tbody></table>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
3

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tbody><tr>
			<td style="width: 50%; width: 49%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Date: February 7, 2024</div>
			</td>
			<td colspan="2" style="width: 38%; width: 4%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>CervoMed Inc.</b></div>
			</td>
			<td style="width: 12%; width: 12%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"></div>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; width: 49%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</div>
			</td>
			<td style="width: 3%; width: 4%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</div>
			</td>
			<td style="width: 35%; width: 35%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</div>
			</td>
			<td style="width: 12%; width: 12%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"></div>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; width: 49%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</div>
			</td>
			<td style="width: 3%; width: 4%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</div>
			</td>
			<td align="left" style="nowrap: nowrap; width: 35%; width: 35%;" valign="bottom">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</div>
			</td>
			<td style="width: 12%; width: 12%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"></div>
			</td>
		</tr>
		<tr>
			<td align="left" style="width: 50%; text-align: left; width: 49%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</div>
			</td>
			<td style="width: 3%; text-align: left; width: 4%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </span></div>
			</td>
			<td align="left" style="nowrap: nowrap; width: 35%; border-bottom: 1px solid rgb(0, 0, 0); width: 35%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">/s/&#160;</span>William Elder</div>
			</td>
			<td style="width: 12%; width: 12%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"></div>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; width: 49%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</div>
			</td>
			<td style="width: 3%; width: 4%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Name:</div>
			</td>
			<td style="width: 35%; width: 35%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">William Elder</div>
			</td>
			<td style="width: 12%; width: 12%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"></div>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; width: 49%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&#160;</div>
			</td>
			<td style="width: 3%; width: 4%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Title:</div>
			</td>
			<td style="width: 35%; width: 35%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">General Counsel</div>
			</td>
			<td style="width: 12%; width: 12%;" valign="top">
			<div style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
4
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_623386.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_623386.htm</title>

	<!-- Generated by ThunderDome Portal - 2/6/2024 11:31:09 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><img alt="logosmall.jpg" src="logosmall.jpg"></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Dr. Boger is the founder, and retired CEO and Board Chair, of Vertex Pharmaceuticals</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>CervoMed on track to complete enrollment in 1H 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies; topline data expected in 2H 2024</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Boston </b>&#8211;<b> February 7, 2024 </b>&#8211; CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company developing treatments for degenerative diseases of the brain, today announced the appointment of Joshua Boger, Ph.D., to its Board of Directors (Board) and as Chair of the Board. Dr. Boger is an innovative scientist and highly successful business executive who brings extensive drug development and biopharmaceutical company leadership experience to CervoMed as it progresses toward an important inflection point. Topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod in dementia with Lewy bodies (DLB) is expected in the second half of 2024. The Board Chair position was formerly held by CervoMed co-founder Dr. Sylvie Gregoire, who will continue to serve as a director.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8220;It is a pleasure to welcome Joshua, the founder of Vertex and an esteemed industry leader, to our Board of Directors,&#8221; said John Alam, M.D., Chief Executive Officer of CervoMed. &#8220;Our lead program, neflamapimod, was licensed from Vertex and has the potential to offer a highly differentiated, first-to-market treatment option for DLB. This is an ideal time for Joshua&#8217;s appointment, and we look forward to leveraging his extensive experience and strategic insights as we progress towards topline efficacy results in RewinD-LB, which has transformational potential for the company. We remain on track to fully enroll RewinD-LB within the first half of this year, followed by topline efficacy results in the second half of 2024.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dr. Boger added, &#8220;I am thrilled to join the team and Board of CervoMed, as neflamapimod has the potential to fundamentally change the lives of patients with DLB and their caregivers. As an investor I&#8217;ve closely followed neflamapimod since 2016. The dramatic progress in the last two years in understanding the mechanism of action against cholinergic degeneration, and the Phase 2a clinical results in DLB, gives me great confidence in neflamapimod&#8217;s potential to successfully advance through Phase 2b and eventually to approval in DLB. I look forward to working closely with CervoMed&#8217;s outstanding team and Board, to lay the foundation for sustained growth and advance the Company&#8217;s mission."</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dr. Joshua Boger is an industry veteran who has served in multiple scientific and business leadership roles in his 40+ year career. He currently serves as Executive Chairman of Alkeus Pharmaceuticals. Dr. Boger founded Vertex in 1989 and was the Chief Executive Officer from 1992 until 2009. He continued to serve on the Vertex Board and Chair Vertex&#8217;s Science &amp; Technology Committee until 2017. Prior to founding Vertex, Dr. Boger was Senior Director of Basic Chemistry at Merck Sharp &amp; Dohme Research Laboratories in Rahway, NJ, where he headed both the Departments of Biophysical Chemistry and Medicinal Chemistry of Immunology &amp; Inflammation. During his 10 years at Merck, Dr. Boger developed an international reputation in the application of computer modeling to the chemistry of drug design and pioneered the use of structure-based rational drug design as the basis for drug discovery programs. Dr. Boger holds a Bachelor of Arts degree in Chemistry and Philosophy from Wesleyan University and a Master's and Doctorate Degree in Chemistry from Harvard University. His postdoctoral research in molecular recognition was performed in the laboratories of the Nobel-prize winning chemist, Jean-Marie Lehn, in Strasbourg, France. He has authored over 50 scientific publications and holds 32 issued U.S. patents in pharmaceutical discovery and development.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</div>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><img alt="logosmall.jpg" src="logosmall.jpg"></div>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About Dementia with Lewy Bodies (DLB)</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DLB is the third most common degenerative disease of the brain (after Alzheimer&#8217;s disease and Parkinson&#8217;s disease), with approximately 700,000 individuals in each of US and EU. Patients with this disease accumulate protein deposits, called Lewy bodies, in the brain&#8217;s nerve cells. This negatively affects cognitive ability, including attention, judgement, and reasoning, along with motor function. Patients with DLB incur higher healthcare costs, have longer hospitalizations, report lower quality of life, and have caregivers with higher levels of distress when compared to patients with Alzheimer&#8217;s disease. No treatments for DLB have been approved by the U.S. FDA or European Medicines Agency, and there are limited drugs in development. The current standard of care is cholinesterase inhibitor therapy, which is approved for use in Alzheimer&#8217;s disease, but in DLB patients only transiently improves cognition and does not impact motor component.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About Neflamapimod </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Neflamapimod is an investigational, orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha (p38a). In preclinical studies, neflamapimod reversed synaptic dysfunction, including and particularly within the part of the brain most impacted in DLB &#8211; the basal forebrain cholinergic system. In Phase 1 and Phase 2 clinical studies involving more than 300 participants, neflamapimod has been shown to be generally well tolerated. Results from the AscenD-LB Phase 2a clinical study demonstrated that neflamapimod significantly improved dementia severity (assessed by Clinical Dementia Rating Sum-of-boxes, or CDR-SB) compared to placebo and significantly improved functional mobility (assessed by Timed Up and Go Test, or TUG test) compared to placebo. At the highest dose evaluated, neflamapimod also improved cognition. The treatment response in AscenD-LB in patients without Alzheimer&#8217;s-related co-pathology (evaluated by a blood test, plasma ptau181) was substantial (effect size &gt; 0.7) and greater than the overall patient population. The combined preclinical and clinical data are consistent with neflamapimod treating the underlying DLB disease process.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div><img alt="logosmall.jpg" src="logosmall.jpg"></div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About the RewinD-LB Phase 2b Study in Dementia with Lewy Bodies</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CervoMed&#8217;s ongoing Phase 2b study, RewinD-LB, is a randomized, 16-week, double-blind, placebo-controlled clinical trial evaluating oral neflamapimod (40mg three times per day) in up to 160 patients with prodromal DLB or mild dementia due to DLB. Patients completing the 16-week placebo-controlled study period will be able to continue in the study while receiving open label neflamapimod treatment for an additional 32 weeks. Patients with AD-related co-pathology, assessed by a blood biomarker (plasma ptau181), will be excluded. The primary endpoint in the study is change in CDR-SB, and secondary endpoints include the TUG test, a cognitive test battery, and the Clinician&#8217;s Global Impression of Change. The RewinD-LB study is funded by a $21 million grant from the National Institutes of Health's National Institute on Aging, which will be disbursed over the course of the study as costs are incurred. The study includes 41 sites (30 in the United States, 8 in the United Kingdom, 3 in the Netherlands), all of which have been initiated. More information on the RewinD-LB study, including contact information on active clinical trial sites, is available at clinicaltrials.gov.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About CervoMed</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for degenerative diseases of the brain. The company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha (p38a). Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that causes disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Forward-Looking Statements</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of the Company, including, but not limited to, the therapeutic potential of neflamapimod and anticipated timing of clinical milestones. Terms such as "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately," "potential" or other words that convey uncertainty of future events or outcomes may identify these forward-looking statements. Although there is believed to be reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company's control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to: the Company's available cash resources and the availability of additional funds on acceptable terms; the results of the Company&#8217;s clinical trials; the likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback the Company may receive from the U.S. Food and Drug Administration; the ability to implement business plans, forecasts, and other expectations in the future; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the three-month period ended September 30, 2023 filed with the U.S. Securities and Exchange Commission (SEC) on November 13, 2023, and other filings that the Company may file from time to time with the SEC. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified). The Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except to the extent required by law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div><img alt="logosmall.jpg" src="logosmall.jpg"></div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Investor Contact: </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PJ Kelleher</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">LifeSci Advisors</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Investors@cervomed.com</u></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">617-430-7579</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Media Contact: </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Tressa Frankel</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Health+Commerce</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">tressa@healthandcommerce.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ex_622961.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<html><head>
	<title>ex_622961.htm</title>

	<!-- Generated by ThunderDome Portal - 2/6/2024 11:29:39 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.2</b></font></p>

<p style="margin: 0px 0pt; text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><img alt="logosmall.jpg" src="logosmall.jpg"></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CervoMed to Participate in the Emerging Growth Conference 67</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Boston </b>&#8211;<b> February 5, 2024 </b>&#8211; CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that Company&#8217;s Management will provide a corporate update at the Emerging Growth Conference 67, to be held virtually from February 7-8, 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Presentation Details </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Format: Corporate presentation</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: Wednesday, February 7, 2024</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Time: 3:50 PM ET</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Registration Link: click here</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A live webcast of the presentation, along with accompanying slides, will be accessible&nbsp;here. A replay of the presentation will also be available through the conference portal and on the Emerging Growth YouTube Channel following the event.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About the Emerging Growth Conference </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products &amp; services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">All sessions will be conducted through video webcasts and will take place in the Eastern time zone.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About CervoMed</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for degenerative diseases of the brain. The Company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha (p38a). Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Investor Contact: </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PJ Kelleher</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">LifeSci Advisors</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Investors@cervomed.com</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">617-430-7579</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>crvo-20240205.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 2/6/2024 11:33:19 PM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:crvo="http://www.crvo.com/20240205" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.crvo.com/20240205">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crvo-20240205_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crvo-20240205_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crvo-20240205_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.crvo.com/20240205/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="crvo_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>crvo-20240205_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 2/6/2024 11:33:19 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.crvo.com/20240205/role/statement-document-and-entity-information" xlink:href="crvo-20240205.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.crvo.com/20240205/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>


<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>crvo-20240205_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 2/6/2024 11:33:19 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:label xlink:label="dei_WrittenCommunications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:label xlink:label="dei_SolicitingMaterial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementIssuerTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>crvo-20240205_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 2/6/2024 11:33:19 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.crvo.com/20240205/role/statement-document-and-entity-information" xlink:href="crvo-20240205.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.crvo.com/20240205/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>

<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>logosmall.jpg
<TEXT>
begin 644 logosmall.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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?@**** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139887217190000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Feb. 05, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">CervoMed Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">Feb.  05,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">001-37942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">30-0645032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">20 Park Plaza, Suite 424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">02116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">744-4400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CRVO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0001053691<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M R1,-YQPWS0/^/SS\_'QWW;[&ZG>]9HQ0[9I(O3 61N3W;FNCM8LI?I:9DS
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M='@//GL?)=-[*CG_5U/\!%!+ P04    " #'@$=8EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( ,> 1U@ZJJ+G0 $
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MEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    ( ,>
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( ,> 1UA#0>>?/ 0  )00   8
M          " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " #'@$=8GZ ;\+$"  #B#   #0              @ %_#   >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( ,> 1UB7BKL<P    !,"   +
M  "  5L/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( ,> 1U@ZJJ+G0 $  #P"
M   /              "  400  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" #'@$=8)!Z;HJT   #X 0  &@              @ &Q$0  >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #'@$=899!YDAD!  #/ P
M$P              @ &6$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
.."0 ) #X"  #@$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="crvo20240205_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crvo.com/20240205/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>crvo-20240205.xsd</File>
    <File>crvo-20240205_def.xml</File>
    <File>crvo-20240205_lab.xml</File>
    <File>crvo-20240205_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="crvo20240205_8k.htm">crvo20240205_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "crvo20240205_8k.htm": {
   "nsprefix": "crvo",
   "nsuri": "http://www.crvo.com/20240205",
   "dts": {
    "schema": {
     "local": [
      "crvo-20240205.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "crvo-20240205_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "crvo-20240205_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "crvo-20240205_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "crvo20240205_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 26,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://www.crvo.com/20240205/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d20248K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20240205_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d20248K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20240205_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.crvo.com/20240205/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.crvo.com/20240205/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.crvo.com/20240205/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.crvo.com/20240205/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.crvo.com/20240205/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.crvo.com/20240205/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.crvo.com/20240205/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.crvo.com/20240205/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.crvo.com/20240205/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.crvo.com/20240205/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.crvo.com/20240205/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.crvo.com/20240205/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.crvo.com/20240205/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.crvo.com/20240205/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.crvo.com/20240205/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.crvo.com/20240205/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.crvo.com/20240205/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.crvo.com/20240205/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.crvo.com/20240205/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.crvo.com/20240205/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.crvo.com/20240205/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.crvo.com/20240205/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.crvo.com/20240205/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.crvo.com/20240205/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.crvo.com/20240205/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001437749-24-003357-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-24-003357-xbrl.zip
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ME$GO BXM;65&M$%6_1<_?P%02P,$%     @ QX!'6'_V)[+7!   Y2P  !4
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M>/P>%^H_-%FX/OG]_NCJNIKFK$O/SZTY/=9><RH,?D33FJJ9>_C_4$L#!!0
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M?4' 0%EDCN@G!?!$5ZTV_'O67G,%F$.FEY(3>69-L\C6V9;$ 2"4=<.+@O>
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M;RTR,#(T,#(P-5]P<F4N>&UL4$L! A0#%     @ QX!'6%#5(+ Z&@  89\
M !,              ( !<!,  &-R=F\R,#(T,#(P-5\X:RYH=&U02P$"% ,4
M    " #'@$=8L1+T7DX&  #Q%P  #0              @ ';+0  97A?-C(R
M.38Q+FAT;5!+ 0(4 Q0    ( ,> 1UBLY?+U,A0  !Q&   -
K  "  50T  !E>%\V,C,S.#8N:'1M4$L%!@     '  < OP$  +%(      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>crvo20240205_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="crvo-20240205.xsd" xlink:type="simple"/>
    <context id="d20248K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
        </entity>
        <period>
            <startDate>2024-02-05</startDate>
            <endDate>2024-02-05</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d20248K" id="ixv-360">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20248K" id="ixv-361">0001053691</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20248K" id="ixv-22">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20248K" id="ixv-35">2024-02-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="d20248K" id="ixv-43">CervoMed Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d20248K" id="ixv-55">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="d20248K" id="ixv-60">001-37942</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="d20248K" id="ixv-65">30-0645032</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d20248K" id="ixv-91">20 Park Plaza, Suite 424</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d20248K" id="ixv-95">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20248K" id="ixv-97">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d20248K" id="ixv-102">02116</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d20248K" id="ixv-116">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d20248K" id="ixv-118">744-4400</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="d20248K" id="ixv-371">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="d20248K" id="ixv-372">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="d20248K" id="ixv-373">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="d20248K" id="ixv-374">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="d20248K" id="ixv-375">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20248K" id="ixv-376">CRVO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20248K" id="ixv-377">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="d20248K" id="ixv-378">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
